The promise of curcumin-phosphatidylcholine complex for cardiometabolic diseases: More than just more curcumin

Natural Product Research

Volumn 29, Issue 5, 2015, Pages 392-393

  Sahebkar, Amirhossein ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CURCUMIN; DEMETHOXYCURCUMIN; LEPTIN; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL;

ARTERIAL STIFFNESS; ATHEROSCLEROTIC PLAQUE; BRUSH BORDER; CARDIOMETABOLIC RISK; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LETTER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PULSE WAVE; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; METABOLIC DISEASES;

CARDIOVASCULAR DISEASES; CURCUMIN; HUMANS; METABOLIC DISEASES; PHOSPHATIDYLCHOLINES;

EID: 84920880090     PISSN: 14786419     EISSN: 14786427     Source Type: Journal    
DOI: 10.1080/14786419.2014.947494     Document Type: Letter

References (14)

1. Almazov VA, Freidlin IS, Krasilnikova EI. 1986. The use of lipostabil to control lipid metabolic disorders in coronary patients. Kardiologiya. 26: 39-42
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm. 4: 807-818
3. Buang Y, Wang YM, Cha JY, Nagao K, Yanagita T. 2005. Dietary phosphatidylcholine alleviates fatty liver induced by orotic acid. Nutrition. 21: 867-873
4. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 25: 144-150
5. Cohn JS, Wat E, Kamili A, Tandy S. 2008. Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol. 19: 257-262
6. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 74: 664-669
7. Eshiginia S, Gapparov MM, Soto K. 2005. Influence of phospholipids on efficiency of dietary therapy and parameters of lipids metabolism in patients with hypertension. Vopr Pitan. 74: 28-31
8. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. 2014. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis. 232: 40-51
9. Jung YY, Nam Y, Park YS, Lee HS, Hong SA, Kim BK, Park ES, Chung YH, Jeong JH. 2013. Protective effect of phosphatidylcholine on lipopolysaccharide-induced acute inflammation in multiple organ injury. Korean J Physiol Pharmacol. 17: 209-216
10. Sahebkar A. 2013b. Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia. Biochim Biophys Acta. 1831: 887-893
11. Sahebkar A. 2013a. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. 39: 197-208
12. Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, Anes E, Kulaksiz H, Füllekrug J, Stremmel W, Griffiths G, Ehehalt R. 2007. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 282: 27155-27164
13. Wendel A. 2000. Lecithin. Kirk-Othmer encyclopedia of chemical technology. New York (NY): Wiley
14. Wojcicki J, Pawlik A, Samochowiec L, Kaldonska M, Mysliwiec Z. 2006. Clinical evaluation of lecithin as a lipid-lowering agent. Phytother Res. 9: 597-599.